DRW Securities LLC Makes New $573,000 Investment in BeiGene, Ltd. (NASDAQ:BGNE)

DRW Securities LLC acquired a new position in shares of BeiGene, Ltd. (NASDAQ:BGNE) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,553 shares of the company’s stock, valued at approximately $573,000.

Several other institutional investors and hedge funds also recently made changes to their positions in BGNE. Point72 Asset Management L.P. acquired a new stake in BeiGene in the 2nd quarter worth about $54,412,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of BeiGene by 160.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 225,854 shares of the company’s stock worth $50,706,000 after purchasing an additional 138,978 shares during the period. XY Capital Ltd acquired a new stake in shares of BeiGene in the third quarter valued at approximately $6,839,000. Affinity Asset Advisors LLC boosted its stake in shares of BeiGene by 33.9% in the second quarter. Affinity Asset Advisors LLC now owns 110,000 shares of the company’s stock valued at $15,694,000 after buying an additional 27,857 shares during the period. Finally, Baillie Gifford & Co. boosted its stake in shares of BeiGene by 0.6% in the third quarter. Baillie Gifford & Co. now owns 3,705,756 shares of the company’s stock valued at $831,979,000 after buying an additional 23,807 shares during the period. Institutional investors and hedge funds own 48.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on BGNE shares. JMP Securities initiated coverage on BeiGene in a report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price objective for the company. JPMorgan Chase & Co. boosted their price target on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday, October 22nd. TD Cowen upped their price objective on shares of BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Citigroup raised their target price on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Finally, StockNews.com downgraded shares of BeiGene from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $247.07.

Insider Activity

In other news, insider Titus B. Ball sold 137 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total value of $26,021.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO John Oyler sold 6,175 shares of BeiGene stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total transaction of $1,433,958.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,070 shares of company stock worth $4,901,050. Insiders own 7.43% of the company’s stock.

BeiGene Stock Up 1.0 %

Shares of NASDAQ BGNE opened at $192.11 on Wednesday. The company has a market cap of $18.71 billion, a price-to-earnings ratio of -23.31 and a beta of 0.63. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. BeiGene, Ltd. has a 12 month low of $126.97 and a 12 month high of $248.16. The stock has a 50-day moving average price of $211.94 and a two-hundred day moving average price of $183.56.

BeiGene (NASDAQ:BGNE) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. BeiGene’s revenue for the quarter was up 28.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.01 earnings per share. As a group, analysts forecast that BeiGene, Ltd. will post -5.38 earnings per share for the current fiscal year.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.